University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Joel Palefsky

Joel Palefsky, M.D.

Infectious disease specialist

Dr. Joel Palesfsky is an expert in infectious diseases and cancers associated with these diseases. His expertise includes the treatment of anal dysplasia, a pre-cancerous condition that may lead to anal cancer and that is caused by the human papillomavirus (HPV). Anal dysplasia occurs in men and women and is especially common among patients infected with the human immunodeficiency virus (HIV). He also pecializes in the biology and development of new treatments for HPV and Epstein-Barr virus.

Palefsky earned a medical degree at McGill University in Montreal, Canada and completed a fellowship in infectious disease at Stanford University. He is a professor of medicine and laboratory medicine at UCSF.

Conditions & Treatments

Clinics

Center for Colorectal Surgery
2330 Post St., Suite 260
San Francisco, CA 94115-1799
Phone: (415) 885-3606
Fax: (415) 885-7678

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Dysplasia Clinic
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143
Phone: (415) 353- 7100
Fax: (415) 353- 4298

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Joel Palefsky

Additional Languages

French

Education

McGill University 1984

Residencies

McGill University, Internal Medicine 1984

Fellowships

Stanford University, Infectious Disease 1988

Selected Research and Publications

  1. Palefsky J. HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges. AIDS. 2012 May 15; 26(8):1035-6.
  2. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. Differential Transmission of HIV Traversing Fetal Oral/Intestinal Epithelia and Adult Oral Epithelia. J Virol. 2012 Mar; 86(5):2556-70.
  3. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012 Feb; 19(2):261-7.
  4. Diouf K, Sawaya GF, Shiboski S, Magure T, Makunike-Mutasa R, Darragh TM, Tuveson J, Chipato T, Palefsky JM, Moscicki AB, Chirenje M, Smith-McCune K. Investigating Potential Associations between Cervical Procedures and HIV Acquisition. ISRN Obstet Gynecol. 2011; 2011:789106.
  5. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011 Oct 27; 365(17):1576-85.
  6. Guimarães MD, Grinsztejn B, Melo VH, Rocha GM, Campos LN, Pilotto JH, Carmo RA, Palefsky JM. Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J Acquir Immune Defic Syndr. 2011 Aug; 57 Suppl 3:S217-24.
  7. Moreira ED, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin. 2011 Jul; 7(7):768-75.
  8. Moscicki AB, Palefsky JM. Human papillomavirus in men: an update. J Low Genit Tract Dis. 2011 Jul; 15(3):231-4.
  9. Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, Giovannelli L, Coutlée F, Hibbitts S, Chu TY, Settheetham-Ishida W, Picconi MA, Ferrera A, De Marco F, Woo YL, Raiol T, Piña-Sánchez P, Cheung JL, Bae JH, Chirenje MZ, Magure T, Moscicki AB, Fiander AN, Di Stefano R, Cheung TH, Yu MM, Tsui SK, Pim D, Banks L. Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis. 2011 Jun 1; 203(11):1565-73.
  10. Arron ST, Skewes-Cox P, Do PH, Dybbro E, Da Costa M, Palefsky JM, Derisi JL. Validation of a diagnostic microarray for human papillomavirus: coverage of 102 genotypes. J Nucleic Acids. 2011; 2011:756905.
  11. Kojic EM, Cu-Uvin S, Conley L, Bush T, Onyekwuluje J, Swan DC, Unger ER, Henry K, Hammer JH, Overton ET, Darragh TM, Palefsky JM, Vellozzi C, Patel P, Brooks JT. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis. 2011 Apr; 38(4):253-9.
  12. Sénécal M, Brisson M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Mansi JA. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect. 2011 Apr; 87(3):209-15.
  13. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3; 364(5):401-11.
  14. Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, Dobson S, Ogilvie G, Petric M. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011 Mar; 18(3):418-23.
  15. Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis. 2011 Jan 1; 203(1):58-65.
  16. Goldstone S, Palefsky JM, Giuliano AR, Moreira ED, Aranda C, Jessen H, Hillman RJ, Ferris DG, Coutlee F, Liaw KL, Marshall JB, Zhang X, Vuocolo S, Barr E, Haupt RM, Guris D, Garner EI. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis. 2011 Jan 1; 203(1):66-74.
  17. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology. 2011 Jan 20; 409(2):211-22.
  18. Palefsky J. Can HPV vaccination help to prevent anal cancer? Lancet Infect Dis. 2010 Dec; 10(12):815-6.
  19. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010 Oct 15; 202(8):1246-53.
  20. Conley L, Bush T, Darragh TM, Palefsky JM, Unger ER, Patel P, Kojic EM, Cu-Uvin S, Martin H, Overton ET, Hammer J, Henry K, Vellozzi C, Wood K, Brooks JT. Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. J Infect Dis. 2010 Nov 15; 202(10):1567-76.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California